Managing the care of patients with AD is challenging for both PCPs and specialists. Available treatments have attempted to alleviate symptoms; however, a recently approved novel anti-amyloid therapy is the first to demonstrate a positive impact on both AD pathophysiology and disease progression if applied early. Despite this groundbreaking advance, hurdles to implementing disease-modifying therapy remain, including diagnostic delays, use of biomarker assessments that establish treatment eligibility, and ongoing monitoring to detect potential adverse events. PCPs and specialists have unique roles in caring for this population, and are well positioned to identify and manage treatment-eligible patients appropriately.
- Provider:Paradigm Medical Communications, LLC
- Activity Link: https://ce.paradigmmc.com/a/ISPPOC
- Start Date: 2024-04-12 05:00:00
- End Date: 2024-04-12 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.75 hours
- Commercial Support: Source: Eisai, Inc. - Amount: 150875.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge, Learner Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest